The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

The data readout from the mid-stage DME study demonstrated that treatment with the candidate resulted in vision gains, non-inferior to Regeneron’s Eylea, at weeks 24 and 36 in the difficult-to ...

The plaintiff alleges that the defendants failed to disclose to investors that Regeneron paid credit card fees to distributors on the condition that distributors did not charge Eylea customers ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ...

Seigerman views the recent court decision regarding the Eylea biosimilar case as a modest setback but believes it does not overshadow Regeneron’s long-term growth potential. He is particularly ...

Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader. The TALON trial ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.